{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:30:15Z","timestamp":1766125815970,"version":"3.48.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal tuberculosis is the most common form of osteoarticular infection, with recommended anti-tuberculosis treatment durations typically being long (9\u201318\u00a0months), even for mild cases, increasing the risks of drug resistance, toxicity, and poor patient adherence. This study aims to explore, in patients with mild spinal tuberculosis, whether a new combination of anti-tuberculosis drugs (containing rifapentine and moxifloxacin) could shorten the treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Analysis<\/jats:title>\n                    <jats:p>This trial is an open-label, randomized, controlled, non-inferiority trial comparing the efficacy and safety of a short-course regimen [6-month anti-TB regimen] containing rifapentine and moxifloxacin with empirical long-course regimen [12-month anti-TB regimen] in the treatment of patients with mild spinal tuberculosis. Patients diagnosed with mild spinal tuberculosis who meet the inclusion and exclusion criteria will be recruited and randomized in a 1:1 ratio to either of the two arms. Empirical long-course regimen includes rifampin, isoniazid, pyrazinamide and ethambutol (2RHZE\/10RH), while short-course regimen includes rifapentine, moxifloxacin, isoniazid and pyrazinamide (2HRtZM\/4HRtM). The primary outcomes are TB-recurrence rate at 24 months after completion of treatment and proportion of participants with grade 3 or higher adverse events during treatment with study medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will provide evidence whether a short-course regimen of anti-TB drugs (2HRtZM\/4HRtM) is non-inferior to the empirical long-course regimen (2RHZE\/10RH) in patients with mild spinal tuberculosis. If non-inferiority is established, it will contribute to a more optimized treatment for spinal tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      This study is registered with\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06917495<\/jats:ext-link>\n                      as NCT06917495.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1684771","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:26:25Z","timestamp":1766125585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifapentine- and moxifloxacin-containing short-course regimens for mild spinal tuberculosis: study protocol for a multicenter, randomized, non-inferiority phase II clinical trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Yue-E","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ji","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Jiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Ze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Zheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Bo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Qun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Van Den Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dkaa061","article-title":"Antibiofilm and intraosteoblastic activities of rifamycins against staphylococcus aureus: promising in vitro profile of rifabutin","volume":"75","author":"Abad","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"Asin-Prieto","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/jac\/dkaa548","article-title":"Infections after spine instrumentation: effectiveness of short antibiotic treatment in a large multicentre cohort","volume":"76","author":"Benavent","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-021-21748-6","article-title":"Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1111\/jan.12656","article-title":"Influence of nursing interventions on adherence to treatment with antituberculosis drugs in children and young people: research protocol","volume":"71","author":"Guix-Comellas","year":"2015","journal-title":"J. Adv. Nurs."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3977\/j.issn.1005-8478.2022.17.01","article-title":"Chinese guidelines for surgical management of spinal tuberculosis (2022 edition)","volume":"30","author":"Hongqi","year":"2022","journal-title":"Orthop. J. China"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1016\/S1473-3099(23)00004-X","article-title":"Post-tuberculosis sequelae in children and adolescents: a systematic review","volume":"23","author":"Igbokwe","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1128\/AAC.23.2.338","article-title":"Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone","volume":"23","author":"Iversen","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"Leroux","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2022.12.005","article-title":"Extrapulmonary tuberculosis in China: a national survey","volume":"128","author":"Li","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(24)00693-7","article-title":"Acute liver failure","volume":"404","author":"Maiwall","year":"2024","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/jac\/dkl091","article-title":"Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty","volume":"57","author":"Malincarne","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/00002281-199407000-00010","article-title":"Mycobacterial and fungal infections of bone and joints","volume":"6","author":"Meier","year":"1994","journal-title":"Curr. Opin. Rheumatol."},{"key":"B16","unstructured":"Notice on further strengthening the prevention and treatment of drug-resistant tuberculosis\n          \n          \n          2023"},{"key":"B17","unstructured":"National tuberculosis control programme (2024-2030)\n          \n          \n          2024"},{"key":"B18","unstructured":"National drug catalogue for basic medical insurance, work-related injury insurance and maternity insurance (2024)\n          \n          \n          2024"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/BRS.0000000000002811","article-title":"Six versus 12 months of anti tubercular therapy in patients with biopsy proven spinal tuberculosis: a single center, open labeled, prospective randomized clinical Trial-A pilot study","volume":"44","author":"Nene","year":"2019","journal-title":"Spine (Phila Pa 1976)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00264-006-0278-5","article-title":"A new classification and guide for surgical treatment of spinal tuberculosis","volume":"32","author":"Oguz","year":"2008","journal-title":"Int. Orthop."},{"key":"B21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00586-012-2337-5","article-title":"Drug therapy in spinal tuberculosis","volume":"22","author":"Rajasekaran","year":"2013","journal-title":"Eur. Spine J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s00586-016-4496-2","article-title":"Is duration of preoperative anti-tuberculosis treatment a risk factor for postoperative relapse or non-healing of spinal tuberculosis?","volume":"25","author":"Ren","year":"2016","journal-title":"Eur. Spine J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00264-020-04608-8","article-title":"Loud and silent epidemics in the third millennium: tuning-up the volume","volume":"44","author":"Romano","year":"2020","journal-title":"Int. Orthop."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ofac474","DOI":"10.1093\/ofid\/ofac474","article-title":"Effectiveness of different antimicrobial strategies for staphylococcal prosthetic joint infection: results from a large prospective registry-based cohort study","volume":"9","author":"Scheper","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/aoj-20-85","article-title":"Biofilm formation in periprosthetic joint infections","volume":"6","author":"Staats","year":"2021","journal-title":"Ann. Jt."},{"key":"B26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jsprm\/snad002","article-title":"Management and outcomes of spinal tuberculosis in Africa: a scoping review protocol","volume":"2023","author":"Tochukwu","year":"2023","journal-title":"J. Surg. Protoc. Res. Methodol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11392","DOI":"10.1038\/ncomms11392","article-title":"Thiol reductive stress induces cellulose-anchored biofilm formation in Mycobacterium tuberculosis","volume":"7","author":"Trivedi","year":"2016","journal-title":"Nat. Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B30","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"B31","volume-title":"Global tuberculosis report 2023","year":"2023"},{"key":"B32","volume-title":"Global tuberculosis report 2024","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/jac\/dkz166","article-title":"Short-course versus long-course antibiotics in prosthetic joint infections: a systematic review and meta-analysis of one randomized controlled trial plus nine observational studies","volume":"74","author":"Yen","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e02637-17","DOI":"10.1128\/AAC.02637-17","article-title":"Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity","volume":"62","author":"Yew","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/ijms20020340","article-title":"The immune escape mechanisms of Mycobacterium tuberculosis","volume":"20","author":"Zhai","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/cid\/ciy346","article-title":"Intermediate susceptibility dose-dependent breakpoints for high-dose rifampin, isoniazid, and pyrazinamide treatment in multidrug-resistant tuberculosis programs","volume":"67","author":"Zuur","year":"2018","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1684771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:26:32Z","timestamp":1766125592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1684771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1684771"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1684771","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1684771"}}